@Digger73 : excellent post.
"As a result, GRP78 expression has been correlated with an adverse prognosis in melanoma, breast, lung, gastric, hepatocellular and prostate cancer, and drug resistance in breast cancer. Given GRP78's reported roles with respect to several cancers, a molecule
such as PAT-SM6 presents a promising anti
-
cancer treatment to the extent it interferes with the function of GRP78 in cancer.
By displaying Such an excellent safety profile, they've ensured the door remains wide open to multiple revenue streams for their products.
Imho, dyor.
pab research summary #1 , page-34
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.37M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 5414724 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 2206958 | 6 |
View Market Depth
| Last trade - 12.32pm 17/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable